Skip to main content

Advertisement

SpringerLink
Log in

Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors?

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Not applicable

Code availability

Not applicable

References

  1. Azam C, Claraz P, Chevreau C, Vinson C, Cottura E, Mourey L, Pouessel D, Guibaud S, Pollet O, Le Goff M, Bardies C, Pelagatti V, Canonge JM, Puisset F (2020) Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. Eur J Clin Pharmacol 76(4):579–587. https://doi.org/10.1007/s00228-020-02828-w

    Article  CAS  PubMed  Google Scholar 

  2. Pinkhas D, Ho T, Smith S (2017) Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development. Cardiooncology 3. https://doi.org/10.1186/s40959-017-0024-8

  3. Suttle A, Ball H, Molimard M, Hutson T, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L (2014) Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 111(10):1909–1916

    Article  CAS  Google Scholar 

  4. Resteghini C, Cavalieri S, Galbiati D, Granata R, Alfieri S, Bergamini C, Bossi P, Licitra L, Locati LD (2017) Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. Best Pract Res Clin Endocrinol Metab 31(3):349–361. https://doi.org/10.1016/j.beem.2017.04.012

    Article  CAS  PubMed  Google Scholar 

  5. de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, Guchelaar HJ, Verheul HM, Gelderblom H (2015) Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Ther Drug Monit 37(3):331–338. https://doi.org/10.1097/ftd.0000000000000141

    Article  PubMed  Google Scholar 

  6. Teo Y, Wee H, Chue X, Chau N, Tan M, Kanesvaran R, Ho H, Chan A (2016) Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. Pharmacogenomics J 16(1):47–53

    Article  CAS  Google Scholar 

  7. Westerdijk K, Desar IM, Steeghs N, van der Graaf WT, van Erp NP, Pharmacology D, Group O (2020) Imatinib, sunitinib and pazopanib: from flat-fixed dosing towards a pharmacokinetically guided personalized dose. Br J Clin Pharmacol 86(2):258–273

    Article  Google Scholar 

  8. Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N (2017) Clinical pharmacokinetics and pharmacodynamics of pazopanib: towards optimized dosing. Clin Pharmacokinet 56(9):987–997. https://doi.org/10.1007/s40262-017-0510-z

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Santoni M, Conti A, Massari F, Arnaldi G, Iacovelli R, Rizzo M, De Giorgi U, Trementino L, Procopio G, Tortora G, Cascinu S (2015) Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer 136(1):1–10. https://doi.org/10.1002/ijc.28715

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Setayesh Sadeghi

  2. Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran

    Mona Kargar

Authors
  1. Setayesh Sadeghi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mona Kargar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mona Kargar.

Ethics declarations

Ethics approval

Not applicable

Consent to participate

Not applicable

Consent for publication

Not applicable

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sadeghi, S., Kargar, M. Is there association between clinically relevant toxicities of pazopanib and sunitinib with the use of weak CYP3A4 and P-gp inhibitors?. Eur J Clin Pharmacol 77, 1427–1428 (2021). https://doi.org/10.1007/s00228-021-03118-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-021-03118-9

Search

Navigation